Venture Capital

New clinical data reveals a breakthrough 'off-the-shelf' cell therapy that could treat severe autoimmune diseases by re-engineering cellular identity.

A tech-enabled CRO enrolled 550+ oncology patients in six months, a feat that signals a major disruption to the slow, costly drug development process.

A new point-of-care PCR test is moving closer to reality in India, promising to revolutionize the fight against tuberculosis and cervical cancer.

Beyond global distribution, a tech giant is investing in its hometown, merging holiday charity with a strategic commitment to cultivating future engineers.

A Houston biotech reports a 100% response rate with its new CAR-T therapy, offering a potential lifeline for patients with a devastatingly rare cancer.

The biotech is advancing a promising myelofibrosis therapy while developing a next-gen 'super drug,' a dual strategy signaling significant growth.

PHOTRON's takeover of AOS Technologies signals a major shift in the high-speed camera market, with deep implications for automotive safety and defense.

As the humanoid robotics market soars towards $7.7B, one firm is recruiting top talent to find the next big winner. What does this move signal to investors?

A new investment narrative targets 'essential' sectors. A deep dive reveals a complex mix of real strategy, verifiable progress, and pure promotion.

A sleepy cat GIF with 2.4B views is now a children's book. We analyze the business strategy behind turning viral fame into a publishing success story.

Ancient Hakka Tulou are more than relics. Discover how these UNESCO sites blend tradition with tech to create a sustainable tourism model for the future.

A new partnership aims to advance a novel antibody for FTLD, a devastating dementia, showcasing a powerful model for biotech innovation and strategic growth.

John Crowley, who fought to save his own children, will now shape the future of medicine as he headlines the landmark 2026 MDA conference.

Fate Therapeutics' latest data suggests its iPSC-derived CAR-T could revolutionize lupus care, moving cell therapy beyond cancer and into the mainstream.

SAB Biotherapeutics' novel T1D therapy shows promise with a unique safety profile, challenging the status quo and offering new hope for patients.

Advanced aerial surveys reveal massive, untapped deposits of copper and nickel in Canada's far north, potentially rivaling the world's largest mineral reserves.

With a fresh $62M in funding, WELLSTAR is accelerating its AI and acquisition strategy ahead of a planned 2026 spinout, aiming to rewire Canadian healthcare.

New data reveals Syndax's Revuforj is a game-changer for leukemia, sparking a battle for market dominance in targeted cancer therapy.

With new leadership and a debt-free balance sheet, EnviroGold pivots to commercialize its mine waste tech, tapping into global critical minerals demand.

A Swiss firm claims a CHF 480M raise and a $300M tech fund, but a closer look reveals a company with virtually no verifiable corporate footprint.